Search results
Results from the WOW.Com Content Network
For many biologics (e.g., monoclonal antibodies), injection site reactions are the most common adverse effect of the drug, and have been reported to have an incidence rate of 0.5–40%. [ 2 ] In trials of subcutaneous administration of oligonucleotides , between 22 and 100% of subjects developed reactions depending on the oligonucleotide.
Fixed drug reactions are common and so named because they recur at the same site with each exposure to a particular medication. [1] Medications inducing fixed drug eruptions are usually those taken intermittently.
In rare cases immunizations can cause serious adverse effects, such as gelatin measles-mumps-rubella vaccine (MMR) causing anaphylaxis, a severe allergic reaction. [13] Allegations particularly focus on disorders claimed to be caused by the MMR vaccine and thiomersal , a preservative used in vaccines routinely given to U.S. infants prior to 2001.
Mechanisms underlying the cause of reactogenicity symptoms. In clinical trials, reactogenicity is the capacity of a vaccine to produce common, "expected" adverse reactions, especially excessive immunological responses and associated signs and symptoms, including fever and sore arm at the injection site.
The risk of first-degree relatives developing the same hypersensitivity reaction is higher than in the general population. [ 1 ] As this syndrome can present secondary to multiple anticonvulsants, the general term "anticonvulsant hypersensitivity syndrome" (AHS) is favored over the original descriptive term "dilantin hypersensitivity syndrome."
[8] [12] [13] [14] Elranatamab is given by subcutaneous injection. [ 8 ] [ 12 ] The most common side effects include cytokine release syndrome , fatigue , injection site reaction , diarrhea , upper respiratory tract infection , musculoskeletal pain , pneumonia , decreased appetite , rash , cough , nausea , and pyrexia (fever).
Generalized bullous fixed drug eruption (GBFDE) most commonly refers to a drug reaction in the erythema multiforme group. [3]: 129 These are uncommon reactions to medications, with an incidence of 0.4 to 1.2 per million person-years for toxic epidermal necrolysis and 1.2 to 6.0 per million person-years for Stevens–Johnson syndrome.
The first is a local reaction of itchiness, eczema-like texture, indurated erythema on the skin at the injection site. The second is a generalized reaction that can show up as a skin lesion resembling a cyst. The localized reaction takes 4–14 days to develop and can take months to heal. [12]